Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
Sponsored by Neothetics, Inc
About this trial
Last updated 10 years ago
Study ID
LIPO-202-CL-18
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 10 years ago
What is this trial about?
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating
the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to
subcutaneous fat in non-obese subjects.
What are the participation requirements?
Inclusion Criteria
- Healthy male or non-pregnant female subjects
- Capable of providing written consent.
- BMI < 30 kg/m2
- Stable diet and exercise routine
- Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat
Exclusion Criteria
- Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
- Plan on starting a weight loss or exercise program during the study.
- Known hypersensitivity to study drugs